Rheumnow Podcast

ACR22 Year in Review Report Deucravacitinib in PsA JAK inhibitors in rheumatic diseases JAK vs TNF inhibitor Infections in RA New Treatments for SLE? Prelude to a Meeting (ACR22) (11.11.2022) Switching Between JAK Inhibiters in RA Tapering Methotrexate with Biologics or JAK Inhibitors in RA Tofacitinib and RA-ILD Upadacitinib vs Adalimumab in PsA using RAPID3

Addressing Sexual Health and STD Prevention in Lupus Patients CAR-T Therapies in Antiphospholipid Antibody Syndrome Copays Reduce Adherence to SLE Medications Diffuse alveolar hemorrhage in antiphospholipid syndrome Hydroxychloroquine Update from ACR22 Low-grade Proteinuria in Non Renal Lupus: Should We be Worried? Photovoice: A New Visual Research Method in Lupus Stop Ordering Repeat ANAs! Timely Fetal Screening Important in Positive Anti-Ro Antibody Pregnancies Life or Organ Threatening SLE: What To Do? Is There Anything New?

ACR22 Daily Recap: Saturday Recap New Treatments for SLE?

A Novel Treatment Response Measurement Tool for Lupus ACR22 Year in Review Report Breakthrough COVID infection in SLE during Omicron era Effect of voclosporin in class V lupus nephritis Lupus, Sex and STDs Poor Medication Adherence in SLE and How to Improve It Prelude to a Meeting (ACR22) (11.11.2022) Should You Repeat the ENA Panel? Urinary Biomarkers in Lupus Urine Proteomics in SLE with Dr. Michelle Petri

Sunday (Day 2): ACR 22 Daily Recap

ACR 2022 Appraisal, Praise & Critique (11.18.2022) Best of ACR Day Two in PSA Efficacy and Safety Results from BE OPTIMAL in PsA JAK inhibitors in rheumatic diseases Oligoarticular PsA: FOREMOST Study Opioid use in PsA and SpA PET CT Imaging to Define Risk of Progression from PSO to PsA PsA and SPA: Cyclers, Switchers, Who is the Winner? Switch vs Cycle in PsA Women vs. Men: Response to Treatment in Seronegative Arthritis

Best of PsA on Day 1 Can computers tell the difference between RA & PsA? Deucravacitinib in PsA Differences in Presentation and Outcomes of Early vs Late Onset PsA Opioids and Health Care Utilization in PsA and AS Patient Reported Outcomes in PsA Using Novel IL 17A Inhibitor PsA Cycling or Switching MOAs The Dietary Intervention in PsA (DIPSA) Study Ultrasound in PsA Upadacitinib vs Adalimumab in PsA using RAPID3

Sunday (Day 2): ACR 22 Daily Recap

Bouncebackability portends increased risk of adverse outcomes in RA Can I stop Methotrexate in RA? Fat and bone are never alone: osteoporotic fracture in RA JAK inhibitors in rheumatic diseases RA: Steroids are bad, again Reproductive health in a post-Roe world Sensor-engineered glove evaluates hand function in RA Tapering Methotrexate with Biologics or JAK Inhibitors in RA Tofacitinib and RA-ILD

ACR22 Daily Recap: Saturday Recap JAK vs TNF inhibitor Infections in RA Opioid and Neuropathic Use After Initiating btsDMARDs in RA Pre-RA Pharmacological Interventions: Delaying is not Enough PreRA to Treat or Not! Prescribing Methotrexate in Post-Roe Era The Great Debate: To Treat or Not to Treat Pre RA To Switch or Not: Biosimilars in Inflammatory Arthritis